ArticleScientific reports2025
Association between cognitive and autonomic dysfunctions in patients with de novo Parkinson's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Parkinson's Disease: Pathophysiology, Treatment Strategies, Wellness Approaches, and Obstacles/Paths Forward.NeuroSci · 2026Review
- Sympathetic Burden Measured Through a Chest-Worn Sensor Correlates with Spatiotemporal Gait Performances and Global Cognition in Parkinson's Disease.Sensors (Basel, Switzerland) · 2025Article
- Epidemiology of autonomic dysfunction in Parkinson's disease (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cognitive decline is a common issue in Parkinson's disease (PD) and significantly affects patients' quality of life. This study explored the relationship between cognitive functions and dysautonomia in de novo PD. We reviewed records of newly diagnosed PD patients from July 2017 to September 2023 who underwent cognitive and autonomic assessments. Cognitive functions were measured using the Korean version of the Montreal Cognitive Assessment (MoCA-K) and the Seoul Neuropsychological Screening Battery, while autonomic functions were evaluated with the SCOPA-AUT questionnaire. Among 155 patients, 82 with de novo PD were included. The mild cognitive impairment (MCI) group exhibited higher SCOPA-AUT scores, particularly in gastrointestinal dysfunction. Multivariable logistic regression identified total SCOPA-AUT scores as significant predictors of MCI, even after adjusting for demographic and clinical factors. Partial correlation analysis showed significant negative associations between SCOPA-AUT scores and cognitive functions, such as memory and executive function. This study highlights a strong link between autonomic dysfunction, including gastrointestinal issues, and cognitive impairment in de novo PD. Monitoring dysautonomia in early-stage PD may aid in identifying patients at risk of cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.